Scholar Rock Holding Corporation (SRRK)
- Previous Close
13.96 - Open
14.05 - Bid 14.45 x 100
- Ask 14.60 x 100
- Day's Range
13.88 - 14.70 - 52 Week Range
5.56 - 21.17 - Volume
473,359 - Avg. Volume
804,701 - Market Cap (intraday)
1.131B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-1.99 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.25
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
scholarrock.comRecent News: SRRK
Performance Overview: SRRK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SRRK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SRRK
Valuation Measures
Market Cap
1.09B
Enterprise Value
868.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.83
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.00%
Return on Equity (ttm)
-68.30%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-165.79M
Diluted EPS (ttm)
-1.99
Balance Sheet and Cash Flow
Total Cash (mrq)
279.94M
Total Debt/Equity (mrq)
27.45%
Levered Free Cash Flow (ttm)
-81.06M